Latest News

Stay up to date with the latest stock market news from around the world. From breaking news written by our finance analysts to event-driven market news on a global scale.

NasdaqGS:BUSE
NasdaqGS:BUSEBanks

Assessing First Busey (BUSE) Valuation After Strong Earnings And Leadership Change

Why First Busey (BUSE) Is Back on Investors’ Radar First Busey (BUSE) has attracted fresh attention after releasing fourth quarter and full year 2025 results, a leadership change, and an update on its long running share repurchase program. See our latest analysis for First Busey. The earnings release, leadership change and share repurchase update have come alongside a 12.27% 90 day share price return and a 39.40% five year total shareholder return, suggesting momentum has been building...
NYSE:LPX
NYSE:LPXForestry

Will Louisiana-Pacific’s New Independent Chair Shift LPX’s Balance Between Oversight And Execution?

Louisiana-Pacific Corporation has announced that, effective February 19, 2026, long-time director F. Nicholas Grasberger III will become independent Chairperson as current Chair and CEO W. Bradley Southern retires from the Board, while President and CEO-elect Jason P. Ringblom joins as a Class III director and two other directors plan to retire in May 2026. This leadership reshaping, pairing an independent Chair with an internal successor as CEO, signals a clearer separation of oversight and...
CPSE:HLUN B
CPSE:HLUN BPharmaceuticals

Do Real-World Vyepti Outcomes Reframe Lundbeck’s Migraine Strategy and Moat Narrative (CPSE:HLUN B)?

H. Lundbeck A/S recently presented six-month real-world data from its 12-month INFUSE study at the 2026 Headache Cooperative of the Pacific Conference in Ojai, California, highlighting outcomes for adults with migraine treated with Vyepti (eptinezumab) after prior preventive anti-CGRP failures. The data showed meaningful improvements in multiple patient-reported outcomes, including an average 6.3 additional "good days" per month, reinforcing the clinical relevance of switching to intravenous...
NYSE:NKE
NYSE:NKELuxury

Is Nike (NKE) Still Pricing In Too Much Growth After Prolonged Share Price Weakness

If you are wondering whether NIKE's current share price offers genuine value or just looks cheap on the surface, this article is designed to walk you through the key numbers in a clear and practical way. NIKE shares last closed at US$62.18, with returns of 4.3% decline over 7 days, 1.7% decline over 30 days, 1.7% decline year to date, 16.9% decline over 1 year, 47.8% decline over 3 years and 53.4% decline over 5 years. This raises questions about how the market is currently viewing its...
ENXTAM:PHARM
ENXTAM:PHARMBiotechs

Why Pharming Group (ENXTAM:PHARM) Is Down 16.3% After FDA Rejects Joenja Pediatric Expansion Plan

In early February 2026, Pharming Group reported that the U.S. FDA issued a Complete Response Letter for its supplemental New Drug Application seeking to extend Joenja’s use to children aged 4 to 11 years with APDS, requesting more pediatric pharmacokinetic data and clarification on a batch-testing analytical method. An important angle for investors is that Joenja’s existing U.S. approval for patients aged 12 and older remains intact, while younger pediatric access now hinges on resolving...
NasdaqGS:KRYS
NasdaqGS:KRYSBiotechs

Assessing Krystal Biotech (KRYS) Valuation After Analyst Optimism On Vyjuvek Expansion And Ophthalmic Pipeline

Analyst optimism and product pipeline in focus Krystal Biotech (KRYS) is back in the spotlight after several major research houses highlighted its potential to evolve into a multi product company, pointing to ophthalmic candidates KB803 and KB801 and the planned geographic expansion of Vyjuvek. See our latest analysis for Krystal Biotech. Those upbeat analyst views have landed alongside strong recent momentum, with Krystal Biotech’s share price at $282.27 and a 30 day share price return of...
NasdaqCM:RKLB
NasdaqCM:RKLBAerospace & Defense

Is It Too Late To Consider Rocket Lab (RKLB) After A 161% One Year Surge?

If you are wondering whether Rocket Lab shares still offer value after a strong run, it helps to step back and consider what the current price might already be taking into account. The stock has seen a 161.3% return over the past year and a very large return over three years. However, over the last 7 days and 30 days it has shown declines of 7.9% and 2.4%, respectively. Recent attention has centered on Rocket Lab's role as a listed space company and ongoing interest in space-related...
NasdaqGS:PENG
NasdaqGS:PENGSemiconductor

Penguin Solutions’ AI-Focused Leadership Shift Might Change The Case For Investing In Penguin Solutions (PENG)

Penguin Solutions has announced that long-time leader Mark Adams has retired as President, Chief Executive Officer and Director, with technology veteran Kash Shaikh stepping in as President, CEO, principal executive officer and Board member effective February 2, 2026, while Adams remains an advisor for nine months to support the transition. Shaikh’s three-decade career across enterprise software, SaaS, AI infrastructure and cybersecurity, most recently as CEO of Securonix and Virtana,...
NasdaqGS:LI
NasdaqGS:LIAuto

How Prolonged Delivery Declines And New Bets At Li Auto (LI) Have Changed Its Investment Story

Li Auto Inc. reported that it delivered 27,668 vehicles in January 2026, bringing its cumulative deliveries to 1,567,883 as the company rolled out an OTA 8.2 software update and continued expanding its nationwide retail and supercharging network in China. The latest data highlight ongoing sales pressure, with January marking the eighth consecutive month of year-on-year delivery declines even as Li Auto restructures R&D and pushes into pure-electric models and humanoid robotics. Next, we...
TSX:BMO
TSX:BMOBanks

A Look At Bank Of Montreal (TSX:BMO) Valuation After TD Securities Buy Upgrade

TD Securities recently upgraded Bank of Montreal (TSX:BMO) to Buy from Hold, pointing to a more favorable return on equity outlook compared with peers, which has drawn fresh attention to the bank’s shares. See our latest analysis for Bank of Montreal. BMO’s share price has been firming up, with a 1-day share price return of 2.15% at CA$189.35 and a 90-day share price return of 9.63%. Its 1-year total shareholder return of 38.78% and 5-year total shareholder return of 140.02% point to momentum...
NasdaqGS:FSUN
NasdaqGS:FSUNBanks

FirstSun Capital Bancorp (FSUN) Is Up 7.3% After Strong 2025 Earnings And Board Refresh - Has The Bull Case Changed?

FirstSun Capital Bancorp recently reported full-year 2025 results showing net interest income rising to US$317.39 million and net income increasing to US$97.94 million, alongside higher earnings per share, while also recording fourth-quarter net charge-offs of US$5.02 million. At the same time, the board is set for change as long-serving director Diane L. Merdian plans to step down and investor Peter E. Murphy, founder and CEO of Wentworth Capital Management, joins as a Class III director...
NasdaqGS:OLMA
NasdaqGS:OLMABiotechs

The Bull Case For Olema Pharmaceuticals (OLMA) Could Change Following CFO Exit Amid Palazestrant Phase 3 Focus

In late January 2026, Olema Pharmaceuticals announced the departure of Chief Operating and Financial Officer Shane Kovacs, with CEO Dr. Sean P. Bohen stepping in as interim Principal Financial Officer while the company launches an immediate search for a new CFO and retains Kovacs as a consultant through August 1, 2026. At the same time, analysts underscored the importance of Olema’s lead breast cancer candidate palazestrant and its upcoming Phase 3 program, framing leadership changes against...
TSE:7203
TSE:7203Auto

Assessing Toyota Motor (TSE:7203) Valuation After A Sustained Share Price Run

Why Toyota Motor stock is on investors’ radar today Toyota Motor (TSE:7203) is drawing attention after recent share price moves, with the stock last closing at ¥3,610 as investors reassess its size, earnings profile, and longer term return record. See our latest analysis for Toyota Motor. The recent 1-day share price return of 2.12% and 7-day share price return of 4.37% sit alongside a 30-day share price return of 7.57% and a 90-day share price return of 18.75%. The 1-year total shareholder...
NYSE:AAT
NYSE:AATREITs

A Fresh Look At American Assets Trust (AAT) Valuation After Recent Share Price Moves

American Assets Trust (AAT) is on some investors’ radar after recent share price moves, with the stock last closing at $18.03 as they reassess this real estate investment trust’s long term return profile. See our latest analysis for American Assets Trust. Recent trading has been a bit choppy, with a small 7 day share price return of 1.18% set against a 90 day share price return decline of 5.01% and a 1 year total shareholder return decline of 20.11%. This suggests that sentiment has softened...
TSE:6586
TSE:6586Machinery

Makita (TSE:6586) Is Up 17.1% After Boosting Guidance and Announcing ¥40B Share Buyback – What's Changed

In late January 2026, Makita Corporation announced a share repurchase program of up to 10,000,000 shares for ¥40,000 million, alongside raising its full‑year guidance for revenue, profit and earnings per share for the year ending March 31, 2026. The company linked its brighter outlook to stable sales despite a challenging demand backdrop and to foreign exchange movements it expects to be more favorable than previously assumed. We’ll now examine how Makita’s upgraded earnings guidance and new...
NYSE:TXT
NYSE:TXTAerospace & Defense

Textron (TXT) Valuation In Focus After Strong Q4 2025 Beat And Cautious 2026 Outlook

Textron (TXT) just paired a strong fourth quarter of 2025 with a cautious 2026 outlook, a combination that has put the stock under pressure as investors reassess the risk and reward trade off. See our latest analysis for Textron. That cautious 2026 guidance has weighed on sentiment in the short term, with a 7 day share price return of 7.48% decline following the results, even though the 90 day share price return of 9.78% and 1 year total shareholder return of 16.20% still point to momentum...
SGX:C2PU
SGX:C2PUHealth Care REITs

Parkway Life REIT (SGX:C2PU) One Off Gain Challenges Stable Earnings Narrative

Parkway Life Real Estate Investment Trust (SGX:C2PU) has wrapped up FY 2025 with fourth quarter revenue of S$39.0 million and net income of S$88.7 million, while trailing twelve month revenue came in at S$156.3 million and net income at S$152.8 million. The trust has seen revenue move from S$145.3 million in the twelve months to Q4 2024 to S$156.3 million in the twelve months to Q4 2025, with trailing EPS at S$0.2342, setting up a results season in which investors are weighing income...
NYSE:SYF
NYSE:SYFConsumer Finance

Is There Still An Opportunity In Synchrony Financial (SYF) After Recent Share Price Pullback

For investors considering whether Synchrony Financial at around US$73.52 offers genuine value or if the easy money has already been made, this article walks through what the current price might be indicating. The stock has seen a 5.1% decline over the last 7 days and a 13.1% decline over the last 30 days, although it still shows a 10.4% return over 1 year and very large gains of more than 7x over 5 years. These recent moves sit against a backdrop of ongoing updates around consumer credit...
NYSE:BBAI
NYSE:BBAIIT

BigBear.ai Partnership With Maqta Tests International Expansion As Losses Persist

BigBear.ai Holdings (NYSE:BBAI) has partnered with Maqta Technologies, the digital arm of Abu Dhabi’s AD Ports Group. The two firms plan to co-develop AI driven customs and border management solutions for global trade and port operations. The agreement signals BigBear.ai’s push beyond its core U.S. defense focus into broader international government technology programs. For investors watching NYSE:BBAI, this partnership comes as the shares trade at $4.78, with a 1 year return of 13.0% but...
NYSE:CUBI
NYSE:CUBIBanks

Customers Bancorp (CUBI) Valuation Check After Strong Earnings Growth And Upbeat 2026 Outlook

Customers Bancorp (CUBI) is back on investors’ radar after reporting fourth quarter and full year 2025 results alongside 2026 guidance, highlighting net interest income, net income and earnings per share figures that reshape expectations. See our latest analysis for Customers Bancorp. Those earnings and 2026 net interest income guidance landed alongside a steady run in the market, with a 30 day share price return of 6.82% and a 90 day share price return of 18.90%. The 1 year total shareholder...
NYSE:MTX
NYSE:MTXChemicals

A Look At Minerals Technologies (MTX) Valuation After 2025 Results And 2026 Guidance

Why the latest earnings matter for Minerals Technologies stock Minerals Technologies (MTX) has come back into focus after releasing its Q4 and full year 2025 results, which combined a full year net loss with record outcomes in key operating segments and fresh guidance for 2026. See our latest analysis for Minerals Technologies. The share price reaction has been fairly constructive, with a 21.02% 90 day share price return and 10.06% year to date, even though the 1 year total shareholder return...